Edgewood Oncology
Brookline, United States · Founded 2023
- Headquarters
- Brookline, Massachusetts
- Employees
- 1–10
- Founded
- 2023
- Business Model
- B2B
- Website
- edgewoodoncology.com
About
Edgewood Oncology is a clinical-stage biotechnology company founded to advance BTX-A51, a novel small molecule multi-kinase inhibitor that co-targets CK1α, CDK7, and CDK9 to synergistically activate programmed cell death in cancer cells. The company is focused on hematologic malignancies and genetically-defined solid tumors, with active Phase 2a clinical programs in acute myeloid leukemia and breast cancer. Operating as a virtual biotech to maximize agility and efficiency, Edgewood acquired the rights to BTX-A51 from Yissum, the technology transfer company of Hebrew University of Jerusalem, in 2023.
Summary
Edgewood Oncology is a Biotech company based in Brookline, United States, founded in 2023.
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Specialty pharmaceutical company
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.